Siemens Healthineers (NYSE:SI) and Hill-Rom (NYSE:HRC) inked a co-marketing agreement to provide an array of point-of-care diagnostic instruments for diabetes to primary healthcare providers in the U.S.
The offering is slated to include Siemens’ DCA Vantage Analyzer for HbA1c testing, the Clinitek Status+ Urine Chemistry Analyzer for kidney testing and Hill-Rom’s Welch Allyn RetinaVue Network and imaging tech for teleretinal exams.
The companies explained that they hope to offer a workflow that can reduce costs for healthcare systems and improve outcomes for patients. Siemens and Hill-Rom touted data showing that reducing a patient’s HbA1c level by 1% cuts their risk of kidney damage in half and reduces their risk of eye damage by 76%.
“A patient’s quality of life declines significantly when chronic diseases remain untreated, which is why testing for comorbidities is so important,” Mike Sampson, SVP of Siemen’s North America point-of-care diagnostics unit, said in prepared remarks.
“Our new commercial relationship with Hill-Rom will provide holistic, easy-to-implement solutions that aid in combating diabetes and related comorbidities while satisfying value-based quality care measures. With operator-friendly analyzers that generate lab-quality results in minutes and capabilities to integrate test results with electronic health records, physicians can make immediate treatment decisions and improve long-term outcomes,” Sampson added.
“Hill-Rom and Siemens Healthineers share a common vision to put patients on a better path to healthcare by providing solutions that allow our customers to transform care delivery with greater efficiency and effectiveness,” Alton Shader, president of Hill-Rom’s front line care business, said. “We have a tremendous opportunity in front of us and we are excited to activate this vision.”
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.